Clinical immunotoxicity of therapeutic proteins
J Descotes, A Gouraud - Expert opinion on drug metabolism & …, 2008 - Taylor & Francis
Therapeutic proteins are proteins engineered in the laboratory for pharmaceutical use.
Although they tend to offer a better safety margin than most synthetic small molecules because …
Although they tend to offer a better safety margin than most synthetic small molecules because …
Relationships between the dynamics of iatrogenic DNA damage and genomic design in mammalian spermatozoa from eleven species
…, JL Fernández, A Gouraud… - Molecular …, 2011 - Wiley Online Library
The dynamic onset of DNA fragmentation in mammalian sperm populations varies widely in
different species when the spermatozoa are incubated in vitro at body temperature for …
different species when the spermatozoa are incubated in vitro at body temperature for …
Male-driven de novo mutations in haploid germ cells
…, J Massonneau, O Simard, A Gouraud… - MHR: Basic science …, 2013 - academic.oup.com
At the sequence level, genetic diversity is provided by de novo transmittable mutations that
may act as a substrate for natural selection. The gametogenesis process itself is considered …
may act as a substrate for natural selection. The gametogenesis process itself is considered …
[HTML][HTML] GLUcose COntrol Safety & Efficacy in type 2 DIabetes, a systematic review and NETwork meta-analysis
…, S Erpeldinger, R Boussageon, A Gouraud… - PLoS …, 2019 - journals.plos.org
Background The last international consensus on the management of type 2 diabetes (T2D)
recommends SGLT-2 inhibitors or GLP-1 agonists for patients with clinical cardiovascular (CV…
recommends SGLT-2 inhibitors or GLP-1 agonists for patients with clinical cardiovascular (CV…
Drug-induced adverse reactions via breastfeeding: a descriptive study in the French Pharmacovigilance Database
C Soussan, A Gouraud, G Portolan… - European journal of …, 2014 - Springer
Purpose Most drugs are excreted in maternal milk and may therefore be ingested by children
during breastfeeding. Data concerning the safety of the use of drugs by breastfeeding …
during breastfeeding. Data concerning the safety of the use of drugs by breastfeeding …
Delayed methotrexate elimination: incidence, interaction with antacid drugs, and clinical consequences?
…, L Karlin, F Bouafia‐Sauvy, A Gouraud… - Hematological …, 2018 - Wiley Online Library
The aim of this retrospective cohort study was to investigate the incidence of delayed
methotrexate elimination in patients treated with high‐dose methotrexate (≥1 g/m 2 ) for …
methotrexate elimination in patients treated with high‐dose methotrexate (≥1 g/m 2 ) for …
Thromboembolic events and thromboprophylaxis associated with immunomodulators in multiple myeloma patients: a real-life study
…, L Marchal, A Baudouin, A Gouraud… - Journal of Cancer …, 2022 - Springer
Purpose The aim of this study is to assess international guidelines implementation concerning
thromboprophylaxis strategy in myeloma patients treated with immunomodulatory drugs. …
thromboprophylaxis strategy in myeloma patients treated with immunomodulatory drugs. …
Tramadol and hypoglycaemia: comparison with other step 2 analgesic drugs
C Bourne, A Gouraud, A Daveluy… - British Journal of …, 2013 - Wiley Online Library
Aims The risk of hypoglycaemia with tramadol ( TRM ) is not well described. Our aim was to
analyze spontaneous reports of hypoglycaemia registered in the F rench Pharmacovigilance …
analyze spontaneous reports of hypoglycaemia registered in the F rench Pharmacovigilance …
Proton pump inhibitor-induced neutropenia: possible cross-reactivity between omeprazole and pantoprazole
A Gouraud, V Vochelle, J Descotes, T Vial - Clinical drug investigation, 2010 - Springer
Proton pump inhibitors (PPIs) are widely used drugs in the treatment or prophylaxis of peptic
ulcer and gastro-oesophageal reflux disease. In addition to their well documented efficacy, …
ulcer and gastro-oesophageal reflux disease. In addition to their well documented efficacy, …
The road to IMT-advanced communication systems: State-of-the-art and innovation areas addressed by the WINNER+ project
A Osseiran, E Hardouin, A Gouraud… - IEEE …, 2009 - ieeexplore.ieee.org
Phases I and II of the WINNER project contributed to the development, integration, and
assessment of new mobile network techniques from 2004 to 2007. Some of these techniques are …
assessment of new mobile network techniques from 2004 to 2007. Some of these techniques are …